These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10465068)

  • 21. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection.
    Eron JJ; Ashby MA; Giordano MF; Chernow M; Reiter WM; Deeks SG; Lavelle JP; Conant MA; Yangco BG; Pate PG; Torres RA; Mitsuyasu RT; Twaddell T
    Lancet; 1996 Dec; 348(9041):1547-51. PubMed ID: 8950881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
    Autran B; Murphy RL; Costagliola D; Tubiana R; Clotet B; Gatell J; Staszewski S; Wincker N; Assoumou L; El-Habib R; Calvez V; Walker B; Katlama C;
    AIDS; 2008 Jul; 22(11):1313-22. PubMed ID: 18580611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
    Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses.
    Kundu SK; Katzenstein D; Valentine FT; Spino C; Efron B; Merigan TC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(4):269-74. PubMed ID: 9292585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Schwartz DH; Graham BS; Matthews TJ; Stablein DM; Frey SE; Belshe RB; Clements ML; Wright PF; Eibl M
    Clin Exp Immunol; 1994 Nov; 98(2):178-84. PubMed ID: 7955519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160.
    Tacket CO; Baqar S; Munoz C; Murphy JR
    AIDS Res Hum Retroviruses; 1990 Apr; 6(4):535-42. PubMed ID: 2187503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response.
    Ratto-Kim S; Sitz KV; Garner RP; Kim JH; Davis C; Aronson N; Ruiz N; Tencer K; Redfield RR; Birx DL
    J Infect Dis; 1999 Feb; 179(2):337-44. PubMed ID: 9878016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD4 anti-idiotype antibodies in volunteers immunized with rgp160 of HIV-1 or infected with HIV-1.
    Keay S; Tacket CO; Murphy JR; Handwerger BS
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1091-8. PubMed ID: 1503823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
    Lee D; Graham BS; Chiu YL; Gilbert PB; McElrath MJ; Belshe RB; Buchbinder SP; Sheppard HW; Koblin BA; Mayer KH; Keefer MC; Mulligan MJ; Celum CL
    J Infect Dis; 2004 Sep; 190(5):903-7. PubMed ID: 15295694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expansion of restricted cellular immune responses to HIV-1 envelope by vaccination: IL-7 and IL-12 differentially augment cellular proliferative responses to HIV-1.
    Kim JH; Loveland JE; Sitz KV; Ratto Kim S; Mclinden RJ; Tencer K; Davis K; Burke DS; Boswell RN; Redfield RR; Birx DL
    Clin Exp Immunol; 1997 May; 108(2):243-50. PubMed ID: 9158092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up.
    Hejdeman B; Leandersson AC; Fredriksson EL; Sandström E; Wahren B; Bratt G
    HIV Med; 2003 Apr; 4(2):101-10. PubMed ID: 12702130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.
    Rosenberg ES; Graham BS; Chan ES; Bosch RJ; Stocker V; Maenza J; Markowitz M; Little S; Sax PE; Collier AC; Nabel G; Saindon S; Flynn T; Kuritzkes D; Barouch DH;
    PLoS One; 2010 May; 5(5):e10555. PubMed ID: 20479938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
    Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
    J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
    Belshe RB; Clements ML; Dolin R; Graham BS; McElrath J; Gorse GJ; Schwartz D; Keefer MC; Wright P; Corey L
    J Infect Dis; 1993 Dec; 168(6):1387-95. PubMed ID: 8245523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of specific T-cell responses in HIV infection.
    Leandersson AC; Bratt G; Hinkula J; Gilljam G; Cochaux P; Samson M; Sandström E; Wahren B
    AIDS; 1998 Jan; 12(2):157-66. PubMed ID: 9468364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
    Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
    N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Belshe RB; Newman FK; Frey SE
    Vaccine; 1992; 10(6):383-8. PubMed ID: 1534641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.